Director Steven Keith Burke filed a Form 4 with the SEC on September 22, 2026, disclosing the acquisition of restricted stock units and a stock option in SCYNEXIS Inc (NASDAQ:SCYX) on September 18, 2026.
Key Highlights
- RSU grant: Burke acquired 5,750 restricted stock units at $0.00, each convertible into one share of common stock upon vesting.
- Vesting schedule (RSUs): One-third of the RSUs vest annually on the anniversary of the grant date, with the first one-third vesting on September 18, 2027, subject to continuous service.
- Stock option grant: Burke also acquired a stock option (right to buy) covering 5,750 shares of common stock at an exercise price of $4.46, expiring September 18, 2036.
- Vesting schedule (option): One-third of the option shares vest on the one-year anniversary of the grant date, with 1/36 of the remaining shares vesting each month over the following 24 months, subject to continuous service.
- Resulting ownership: Following the transactions, Burke directly holds 5,750 shares of common stock and 5,750 derivative securities beneficially owned.
- Role: Burke is identified in the filing as a Director of SCYNEXIS Inc.
SCYNEXIS Director Burke Receives Equity Awards in September 2026
According to the Form 4 filed on September 22, 2026, Steven Keith Burke, a Director of SCYNEXIS Inc, received two equity awards on September 18, 2026. The first award consisted of 5,750 restricted stock units (RSUs), acquired at a price of $0.00. The filing notes that each RSU entitles Burke to receive one share of common stock upon vesting, with one-third vesting annually on the anniversary of the grant date. The first tranche is scheduled to vest on September 18, 2027, provided Burke is delivering continuous services on that date.
The second award is a stock option granting Burke the right to buy 5,750 shares of common stock at an exercise price of $4.46 per share, with an expiration date of September 18, 2036. Per the filing, one-third of the shares subject to the option vest on the one-year anniversary of the grant date, and 1/36 of the shares vest on each of the next 24 months thereafter, again contingent on continuous service. Both awards were acquired via transaction code "A" (acquired) and are held directly.
Following these transactions, the filing reports that Burke directly and beneficially owns 5,750 shares of common stock and holds 5,750 derivative securities. The Form 4 was signed by Robert F. Joyce Jr., by Power of Attorney, on September 22, 2026.
What Was Disclosed
The filing disclosed two equity grants to SCYNEXIS Director Steven Keith Burke: 5,750 RSUs and a stock option for 5,750 shares at $4.46, both dated September 18, 2026, with multi-year vesting schedules tied to continuous service.



Please wait processing your request...